Multiple SclerosisPhase 3NCT01610700
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A Phase 3 study testing GW-1000-02 in people with Multiple Sclerosis, run by Jazz Pharmaceuticals at 1 site in United Kingdom.
Trial summary
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- GW-1000-02
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 160 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- May 2001to Jul 2002
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged at least 18 years.
- Multiple Sclerosis of any type.
- Stable Multiple Sclerosis symptomatology during the four weeks before study entry.
- Symptoms of the required severity (>50 mm on a 100 mm Visual Analogue Scale severity scale) in least one of the specified impairment categories; spasticity, muscle spasms, disturbed bladder control, neuropathic pain, limb tremor.
- A stable medication regime during the four weeks before study entry.
- Willing to abstain from cannabis or cannabinoids for at least seven days before study entry, and during the study.
Show all 12Show fewer
- Agreed either to use effective contraception during the study and for three months thereafter, or had been surgically sterilised or, if female, were post-menopausal.
- Clinically acceptable laboratory results for pre-study screening.
- Willing and able to undertake and comply with all study requirements.
- Willing and able to read, consider and understand the subject information and consent form and give written informed consent. Subjects unable to read or to sign the document procedures were treated as detailed in the Declaration of Helsinki.
- Willing for their general practitioner, and consultant if appropriate, to be informed of study participation.
- Willing for their name to be notified to Home Office for participation in the study.
Who cannot join
- Known or strongly suspected to be abusing drugs, including alcohol.
- Not prepared to abstain from cannabis or cannabinoids during the study.
- Current or past addiction to cannabis.
- Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
- History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness or personality disorder other than depression associated with chronic illness.
- Received any drug containing levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
Show all 14Show fewer
- Serious cardiovascular disorder including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
- Significant renal or hepatic impairment as shown in medical history or indicated by laboratory results.
- History of epilepsy.
- Terminal illness or other condition in which placebo medication would be inappropriate.
- Pregnant, lactating or at risk of pregnancy.
- Participated in any other clinical research study during the 12 weeks before study entry.
- Planned hospital admission between study entry and Visit 6.
- Planned travel outside the UK between study entry and Visit 6.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
Read the detailed description
Eligible subjects entered a one to two week baseline period; followed by a six week double blind, randomised, parallel group comparison of GW-1000-02 with placebo, self-titrated to symptom resolution or maximum tolerated dose. Existing medication continued at a constant dose.
Primary efficacy comparisons were made between symptom scores recorded during baseline and scores recorded at the end of the parallel group period.
- Conditions
- Multiple Sclerosis
- Being tested
- GW-1000-02, Placebo
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GW-1000-02Drug
Also called Sativex
Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
PlaceboDrug
Each actuation of placebo delivered the excipients only.
| Study group | Role | What they receive |
|---|---|---|
| GW-1000-02 | Experimental | Active treatment Receives: Drug: GW-1000-02 |
| Placebo | Placebo comparator | Control Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment
This was achieved by measuring the change from baseline after six weeks of therapy in the severity of the primary impairment, a composite score from one of five Multiple Sclerosis symptom categories that subjects nominated as their most severe symptom. The severity scores were recorded using a 100 mm Visual Analogue Scale, where 0 = no problem and 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Secondary outcomes (24)
Change From Baseline in Spasticity Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Severity scores over the last 24 hours were recorded using a 100 mm Visual Analogue Scale on one nominated day each week. Scores ranged from 0 = no problem to 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Change From Baseline in Pain Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Severity scores were recorded using a 100 mm Visual Analogue Scale. Scores ranged from 0 = no problem to 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Change From Baseline in Muscle Spasm Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Severity scores were recorded using a 100 mm Visual Analogue Scale. Scores ranged from 0 = no problem to 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Change From Baseline in Tremor Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Severity scores were recorded using a 100 mm Visual Analogue Scale. Scores ranged from 0 = no problem to 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Change From Baseline in Bladder Problems Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Severity scores were recorded using a 100 mm Visual Analogue Scale. Scores ranged from 0 = no problem to 100 = very bad. A decrease in score indicates an improvement.
Measured: baseline and 6 weeks
Subject Global Opinion of Effect on Multiple Sclerosis at the End of Treatment
A 7-point Likert-type scale was used, with the question: 'Please assess the status of your multiple sclerosis since entry into the study using the scale below' with the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse". At Visit 2 (Baseline) patients wrote a brief description of their Multiple sclerosis which was used at end of treatment to aid their memory regarding their symptoms at study start. The number of subjects that considered their condition to be better or much better at the end of treatment is presented.
Measured: 6 weeks
Change From Baseline in Modified Ashworth Scale Score at the End of Treatment
All 20 muscle groups were assessed for spasticity (using a 1-5 scale): 1= no increase in muscle tone to 5= passive movement is difficult and affected part is rigid in flexion or extension. The score for all 20 muscle groups were added to give a total score out of 100; minimum score was 20. A decrease in score indicates an improvement in condition. As such, a negative value indicates an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Beck's Depression Inventory (BDI-II) Score at the End of Treatment
This was a 21-question multiple choice self-report inventory. Subjects' responses to the 21 questions were assigned a score ranging from zero (good) to three (bad), indicating the severity of the symptom. The sum of all BDI-II question scores indicated the severity of depression; score range 0-63. A decrease in score indicates an improvement in condition. As such, a negative value indicates in improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Fatigue Severity Scale Questionnaire Score at the End of Treatment
The Fatigue Severity Scale is a nine-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 0-6 scale (0= no fatigue and 6= severe fatigue). As such a decreased score indicates improvement, and a negative value indicates and improvement from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Rivermead Mobility Index Score at the End of Treatment
The Rivermead Mobility Index is a measure of subject self-mobilisation and was developed to enable rehabilitation professionals to document the effect(s) of interventions. This consisted of 15 questions relating to the dexterity and/or mobility of the patient. Each question had a 'yes' / 'no' answer which was scored as yes=1 no=0. The summary parameter was the total for the 15 questions, with a maximum score of 15. An increased score indicates improvement. As such, a positive value indicates an improvement in score from baseline.
Measured: Baseline and 6 weeks
Change From Baseline in the Mean Total 28-item General Health Questionnaire Score at the End of Treatment
The 28-item General Health Questionnaire is a self-reported questionnaire for the detection of non-psychotic mental disorders (anxiety and depression) in the community and primary care settings. A series of four subscale scores (ranging from 0 [good] to 21 [bad]) were combined to give a total score, which ranged from 0 (good) to 84 (bad). As such, a negative value indicates an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Nine-hole Peg Test Score at the End of Treatment
The Nine-Hole Peg Test is a board with nine holes into which subjects have to insert nine pegs and is designed to test dexterity and coordination. Scores range from 0 (good) to 60 (bad). As such a decrease in score indicates an improvement, and a negative value indicates an improvement from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Total Bladder Control Test Score at the End of Treatment
The total bladder control test score was the sum score from fifteen questions were each scored on a 0-2 scale (one question 0-3), where 0 = good and 2/3 = bad. Ten questions were related to bladder symptoms and control and five were related to the effects on the patient's life. The summary parameters were the total score with a minumum possible score of 0 and a maximum possible score of 31. A decrease in score indicates an improvement, as such a negative value indicates an improvement in condition from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Tremor Activities of Daily Living Scale Score at the End of Treatment
The tremor activities of daily living scale is a patient self-reported questionnaire which consists of 25 questions relating to the effect of tremors on different day-to-day activities, such as eating, drinking, threading a needle and tying a shoe. The ability to perform these tasks was scored on a scale of 0 (unable) to 3 (completely able). The summary parameter was the total score with a minimum of 0 (unable to perform tasks) and a maximum of 75 (completely able to perform tasks). As such, a positive value indicates an improvement in condition from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Ten-metre Mobility Score at the End of Treatment
The 10 Metre Mobility Score is a four point scale assessing a subject's level of mobility. The time taken to walk ten metres was measured for the subset of subjects who were able to walk. A decrease in time indicates an improvement in condition.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Sleep Quality 100 mm Visual Analogue Scale Score at the End of Treatment
Sleep quality scores were rated using a 100 mm visual analogue scale where 0 = best and 100 = worst. As such, a negative value is indicative of an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Sleep Amount 100 mm Visual Analogue Scale Score at the End of Treatment
Sleep amount was rated using a 100 mm visual analogue scale where 0 = best and 100 = worst. As such, a negative value is indicative of an improvement in score from baseline.
Measured: Baseline and 6 weeks
Change From Baseline in the Mean Feeling Upon Wakening 100 mm Visual Analogue Scale Score at the End of Treatment
Sleep amount was rated using a 100 mm visual analogue scale where 0 = best and 100 = worst. As such, a negative value is indicative of an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Barthel Activities for Daily Living Scale Score at the End of Treatment
The Barthel Index consists of 10 items that measure a person's daily functioning, specifically the activities of daily living and mobility. The items include feeding, moving from wheelchair to bed and return, grooming, transferring to and from a toilet, bathing, walking on level surface, going up and down stairs, dressing, continence of bowels and bladder. The person receives a score based on whether they have received help while doing the task. The ability to undertake the 10 different daily activities was assessed on scales of 0-1, 0-2 or 0-3, with 0 indicative of the poorest outcome and the highest possible score indicative of the best outcome. The summary parameter was the total score for each of the ten items, with a minimum possible score of 0 and a maximum possible score of 20. An increased score indicates an improvement, with a change of two or greater in the total score indicating a clinically relevant change. A positive value therefore indicates an improvement from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Short Orientation-Memory-Concentration Test at the End of Treatment
The Short Orientation-Memory-Concentration test is a questionnaire designed to measure orientation, concentration on simple tasks and learning and recall of simple information. The test consists of six items, such as 'what year is it now?' and 'count backwards from 20 to 1'. Each item was scored between 0 (maximum number of errors) and three-10 (best score; no errors), with a point deducted for each error. The summary parameter was the total score from the sum of scores for each item, with an overall possible maximum score of 28 (no errors). Scores over 20 are considered 'normal'. As such, an increased score indicates an improvement, and a positive value indicates an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Reading Visual Acuity Test Score at the End of Treatment
Assessment of reading visual acuity was made using a standard reading chart. Scores could range from 1 (good) to 20 (bad), indicating good and poor eyesight, respectively. As such, a negative value from baseline indicates an improvement in eyesight.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Care-Giver Strain Index Score at the End of Treatment
The Caregiver Strain Index is a 13-item questionnaire designed to detect strain in those that care for subjects. Carers were asked if they found certain situations difficult (i.e. work adjustments, family adjustment, emotional adjustments, physical effort). Each question was scored zero (answered no) or one (answered yes), and was recorded for each of the 13 questions. The summary parameter was the total score, which was the sum score of the 13 questions, giving a minimum possible score of 0 (no strain) and maximum possible score of 13 (maximum possible strain). As such a negative value from baseline indicates an improvement in caregiver strain.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Guy's Neurological Disability Scale Score at the End of Treatment
The Guy's Neurological Disability Scale has 12 separate categories which include cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and 'others'. Each category consists of a series of questions, which are scored on a 0 to 5 scale, with 0 being indicative of a better outcome and 5 being indicative of a worse outcome. The total Guy's Neurological Disability Scale score is the unweighted sum from the 12 categories with a minimum score of 0 and maximum of 60. A negative value indicates an improvement in score from baseline.
Measured: baseline and 6 weeks
Change From Baseline in the Mean Total Adult Memory and Information Processing Battery Test Score at the End of Treatment
The Adult Memory and Information Processing Battery test comprises six sub-sections which assess cognition and mental alertness. These include immediate and delayed story recall, word-list learning, copying a complex figure followed by its immediate reproduction, design learning, and information processing (parts A and B). The sum score for each section gave the total score which ranged from 1 (bad) to 105 (good). As such, a positive value indicates an improvement in score from baseline.
Measured: baseline and 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2012 (estimated)
- Study startMay 2001
- Primary completionJul 2002
- Study completionJul 2002
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Jazz PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jazz Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01610700
- Sponsor's protocol ID
- GWMS0001 Part A
- Status last verified
- Dec 2022
- First submitted
- 31 May 2012
- Last updated
- 12 Jan 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa.
PubMed 15327042
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension
- ClinicalTrials.gov ID
- NCT01610700
- Acronym / sponsor ID
- GWMS0001 Part A
- Conditions
- Multiple Sclerosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- Jazz PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- May 2001
- Primary completion
- Jul 2002 (actual)
- Study completion
- Jul 2002 (actual)
- First posted
- 4 Jun 2012 (estimated)
- Results
- Posted 19 Sep 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
Detailed description
Eligible subjects entered a one to two week baseline period; followed by a six week double blind, randomised, parallel group comparison of GW-1000-02 with placebo, self-titrated to symptom resolution or maximum tolerated dose. Existing medication continued at a constant dose.
Primary efficacy comparisons were made between symptom scores recorded during baseline and scores recorded at the end of the parallel group period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GW-1000-02 | Experimental | Drug: GW-1000-02Active treatment |
| Placebo | Placebo comparator | Drug: PlaceboControl |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Aged at least 18 years.
- Multiple Sclerosis of any type.
- Stable Multiple Sclerosis symptomatology during the four weeks before study entry.
- Symptoms of the required severity (>50 mm on a 100 mm Visual Analogue Scale severity scale) in least one of the specified impairment categories; spasticity, muscle spasms, disturbed bladder control, neuropathic pain, limb tremor.
- A stable medication regime during the four weeks before study entry.
Key exclusion criteria (14 listed)
- Known or strongly suspected to be abusing drugs, including alcohol.
- Not prepared to abstain from cannabis or cannabinoids during the study.
- Current or past addiction to cannabis.
- Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
- History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness or personality disorder other than depression associated with chronic illness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GW-1000-02Also: SativexContaining THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period. | Drug | GW-1000-02 |
| PlaceboEach actuation of placebo delivered the excipients only. | Drug | Placebo |
Primary outcome
Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
This was achieved by measuring the change from baseline after six weeks of therapy in the severity of the primary impairment, a composite score from one of five Multiple Sclerosis symptom categories that subjects nominated as their most severe symptom. The severity scores were recorded using a 100 mm Visual Analogue Scale, where 0 = no problem and 100 = very bad. A decrease in score indicates an improvement.
24 secondary outcomes
Change From Baseline in Spasticity Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in Pain Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in Muscle Spasm Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in Tremor Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in Bladder Problems Visual Analogue Scale Score at the End of 6 Weeks of Treatment
Time frame: baseline and 6 weeks
Subject Global Opinion of Effect on Multiple Sclerosis at the End of Treatment
Time frame: 6 weeks
Change From Baseline in Modified Ashworth Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Beck's Depression Inventory (BDI-II) Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Fatigue Severity Scale Questionnaire Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Rivermead Mobility Index Score at the End of Treatment
Time frame: Baseline and 6 weeks
Change From Baseline in the Mean Total 28-item General Health Questionnaire Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Nine-hole Peg Test Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Total Bladder Control Test Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Tremor Activities of Daily Living Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Ten-metre Mobility Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Sleep Quality 100 mm Visual Analogue Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Sleep Amount 100 mm Visual Analogue Scale Score at the End of Treatment
Time frame: Baseline and 6 weeks
Change From Baseline in the Mean Feeling Upon Wakening 100 mm Visual Analogue Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Barthel Activities for Daily Living Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Short Orientation-Memory-Concentration Test at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Reading Visual Acuity Test Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Care-Giver Strain Index Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Guy's Neurological Disability Scale Score at the End of Treatment
Time frame: baseline and 6 weeks
Change From Baseline in the Mean Total Adult Memory and Information Processing Battery Test Score at the End of Treatment
Time frame: baseline and 6 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 15327042Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing GW-1000-02 in people with Multiple Sclerosis, run by Jazz Pharmaceuticals at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Sep 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (time frame: baseline and 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01610700, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2023.